Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study
Titel:
Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study
Auteur:
Cusi, Kenneth Alkhouri, Naim Harrison, Stephen A Fouqueray, Pascale Moller, David E Hallakou-Bozec, Sophie Bolze, Sebastien Grouin, Jean-Marie Jeannin Megnien, Sophie Dubourg, Julie Ratziu, Vlad